Last reviewed · How we verify
Other anti-cancer therapy — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Other anti-cancer therapy (Other anti-cancer therapy) — Mabwell (Shanghai) Bioscience Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Other anti-cancer therapy TARGET | Other anti-cancer therapy | Mabwell (Shanghai) Bioscience Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Other anti-cancer therapy CI watch — RSS
- Other anti-cancer therapy CI watch — Atom
- Other anti-cancer therapy CI watch — JSON
- Other anti-cancer therapy alone — RSS
Cite this brief
Drug Landscape (2026). Other anti-cancer therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/other-anti-cancer-therapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab